BIOLIFE SOLUTIONS INC
Company Stats
- Market Cap
- $1.9B
- as of Sep 30, 2026
- Enterprise Value
- $1.9B
- Shares Outstanding
- 48.9M
- Free Float
- 83.0%
Income Statement
- Revenue
- $96.2M
- Operating Income
- -$16.6M
- Net Income
- -$4.6M
- EBITDA
- -$14.3M
- Revenue Growth, 3Y
- 8.1%
- FCF Margin, 3Y Avg
- -3.2%
- FCF Margin, Worst Year
- -27.8%
Cash Flow
- Free Cash Flow
- $10.6M
- FCF Yield
- 0.6%
- Owner FCF Yield
- -0.7%
Balance Sheet
- Cash & Equivalents
- $33.0M
- Total Debt
- $5.0M
- Net Cash
- $28.0M
Returns & Capital
- SBC, 3Y Avg
- $29.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $96.2M | $10.6M | 11.1% |
| FY2024 | $74.6M | $5.2M | 7.0% |
| FY2023 | $68.0M | -$18.9M | -27.8% |
| FY2022 | $76.2M | -$18.9M | -24.8% |
| FY2021 | $119.2M | -$13.0M | -10.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Coverage
October 6, 2026
Deals
Repligen Completes $1.5 Billion BioLife Solutions Acquisition
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 23, 2026
Deals
Repligen to Buy BioLife in $1.5 Billion Cash-and-Stock Deal
July 22, 2026
Deals
Repligen to Buy BioLife Solutions in $1.5 Billion Mixed Deal
Repligen Completes $1.5 Billion BioLife Solutions Acquisition
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 23, 2026
Deals
Repligen to Buy BioLife in $1.5 Billion Cash-and-Stock Deal
July 22, 2026
Deals
Repligen to Buy BioLife Solutions in $1.5 Billion Mixed Deal